How to Help Your Patients Find Xigduo XR in Stock: A Provider's Guide

Patients prescribed Xigduo XR (dapagliflozin/metformin HCl extended-release) are navigating a complicated medication access landscape in 2026. Between the brand-to-generic transition, insurance formulary restrictions, and pharmacy-level inventory variability, many patients are calling your office frustrated and without their medication.

This guide gives you concrete workflows and patient-facing tools to reduce access disruptions and keep your patients on therapy.

Understand the Current Access Landscape

Before addressing a patient's access problem, it helps to understand why it exists:

No official shortage: Xigduo XR is not on the FDA shortage list, but availability is inconsistent at the pharmacy level in 2026.

Generic transition: FDA approved generic dapagliflozin/metformin ER in early 2026; distribution is still ramping up.

Insurance barriers: Most Medicare and many commercial plans require prior authorization or step therapy before covering Xigduo XR brand.

Pharmacy inventory: Individual pharmacies stock based on local demand patterns — availability varies significantly from one pharmacy to the next.

Proactive Prescribing Strategies

The following prescribing adjustments can prevent access problems before they start:

1. Enable Generic Substitution

When writing Xigduo XR, ensure the prescription allows generic substitution (DAW=0 in most e-prescribing systems). This permits pharmacists to dispense FDA-approved generic dapagliflozin/metformin ER from manufacturers like Aurobindo or Lupin when brand is out of stock, without needing to contact your office for a new prescription.

2. Consider Prescribing Components Separately

Prescribing dapagliflozin (Farxiga or generic) plus generic metformin XR as two separate prescriptions is pharmacologically equivalent to Xigduo XR and often results in better pharmacy availability, lower patient cost, and easier insurance processing. Generic metformin XR is universally stocked; generic dapagliflozin is widely available since 2025.

For patients on Xigduo XR 10/1000 mg, this would translate to dapagliflozin 10 mg QD plus metformin ER 1000 mg QD — both taken in the morning with food. Note: patients should understand they'll be taking two pills.

3. Submit Prior Authorizations Proactively

If a new patient has insurance that requires prior authorization for Xigduo XR or its generic, submit the PA at the time of prescribing — before the patient heads to the pharmacy. Key documentation to include:

Diagnosis codes: E11.xx (T2DM) plus any applicable I50.xx (HF) or N18.xx (CKD)

Clinical rationale: cardiovascular risk reduction, heart failure management, CKD progression reduction

Prior drug trials: document any step therapy drugs tried and why they were insufficient or not tolerated

Lab values: recent eGFR, A1C, urine albumin-to-creatinine ratio as applicable

4. Prescribe 90-Day Supplies for Stable Patients

For patients who are stable on Xigduo XR or its generic, 90-day mail-order prescriptions dramatically reduce access disruptions. Patients refill every three months rather than monthly, giving them a larger buffer and more time to resolve any stock issues. Many insurance plans also have lower copays for mail-order fills.

Responding When a Patient Can't Fill Their Prescription

When a patient calls reporting they can't fill Xigduo XR, here's a recommended workflow:

Confirm how many days of medication they have left: If they have at least 7 days, they have time to resolve the issue without a bridge prescription.

Ask if they've tried the generic: Many patients asking for "Xigduo XR" haven't asked about the generic equivalent by name.

Recommend medfinder: Direct the patient to medfinder.com, where they can enter their medication and location and have pharmacies called on their behalf.

Send separate prescriptions: Electronically prescribe dapagliflozin + metformin XR separately with instructions to take both.

Escalate if approaching zero supply: If the patient is out of medication, contact a pharmacy directly or write a bridge prescription for a therapeutic equivalent.

Patient Resources to Share

Consider sharing these resources with patients who are having access difficulty:

medfinder.com — calls pharmacies near the patient to check which ones have Xigduo XR or its generic in stock

AZ&Me Prescription Savings Program (1-800-292-6363) — for uninsured or underinsured patients who need brand Xigduo XR

AstraZeneca Savings Card — eligible commercially insured patients may pay as low as $0 per 30-day supply (max $175/fill)

GoodRx — for comparing generic dapagliflozin/metformin ER prices across pharmacies; generic as low as $168/month at some pharmacies

Looking Ahead

As generic dapagliflozin/metformin ER becomes more widely distributed through 2026, the access landscape will improve substantially. For most of your patients, the combination tablet will become more affordable and consistently available. Until then, proactive prescribing strategies and equipping patients with access tools are the most effective interventions available.

For a broader clinical overview, see our article: Xigduo XR shortage: What providers and prescribers need to know in 2026.